18,381 Boston Scientific Corporation $BSX Shares Bought by Salem Investment Counselors Inc.

by · The Cerbat Gem

Salem Investment Counselors Inc. grew its stake in Boston Scientific Corporation (NYSE:BSX – Free Report) by 9.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 207,191 shares of the medical equipment provider’s stock after purchasing an additional 18,381 shares during the period. Salem Investment Counselors Inc.’s holdings in Boston Scientific were worth $9,044,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. BlackRock Inc. bought a new position in shares of Boston Scientific during the 2nd quarter worth approximately $5,534,781,000. Primecap Management Co. CA bought a new stake in Boston Scientific in the second quarter valued at $2,156,233,000. Janus Henderson Group PLC grew its position in Boston Scientific by 5.2% in the fourth quarter. Janus Henderson Group PLC now owns 12,589,385 shares of the medical equipment provider’s stock valued at $1,200,404,000 after acquiring an additional 617,515 shares during the period. Amundi grew its position in Boston Scientific by 13.8% in the first quarter. Amundi now owns 14,122,913 shares of the medical equipment provider’s stock valued at $886,213,000 after acquiring an additional 1,707,754 shares during the period. Finally, Arrowstreet Capital Limited Partnership raised its stake in Boston Scientific by 25.9% during the first quarter. Arrowstreet Capital Limited Partnership now owns 13,891,668 shares of the medical equipment provider’s stock worth $871,702,000 after acquiring an additional 2,856,040 shares in the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Trading Down 1.2%

Shares of NYSE BSX opened at $43.33 on Wednesday. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. The company has a market cap of $62.79 billion, a PE ratio of 17.54, a P/E/G ratio of 1.05 and a beta of 0.58. The company has a 50-day moving average of $46.35 and a two-hundred day moving average of $50.16. Boston Scientific Corporation has a 1-year low of $41.38 and a 1-year high of $105.65.

Boston Scientific (NYSE:BSX – Get Free Report) last posted its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.83 by $0.03. The firm had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%. The business’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, equities analysts expect that Boston Scientific Corporation will post 3.25 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have issued reports on BSX shares. Canaccord Genuity Group cut their price objective on Boston Scientific from $70.00 to $66.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Sanford C. Bernstein reiterated an “outperform” rating and set a $54.00 target price (down from $60.00) on shares of Boston Scientific in a research report on Saturday, October 3rd. TD Cowen reiterated a “buy” rating on shares of Boston Scientific in a research report on Thursday, September 17th. JPMorgan Chase & Co. cut their price target on shares of Boston Scientific from $80.00 to $56.00 and set an “overweight” rating for the company in a report on Thursday, July 30th. Finally, Wells Fargo & Company reduced their price target on shares of Boston Scientific from $50.00 to $48.00 and set an “equal weight” rating on the stock in a research report on Wednesday, September 23rd. One research analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $68.43.

Check Out Our Latest Stock Report on BSX

Insider Transactions at Boston Scientific

In other news, CEO Michael F. Mahoney acquired 186,240 shares of the company’s stock in a transaction on Monday, August 3rd. The stock was purchased at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the acquisition, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at $76,845,859.92. This trade represents a 13.27% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director David C. Habiger bought 2,100 shares of the business’s stock in a transaction on Wednesday, August 5th. The shares were acquired at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the transaction, the director owned 17,160 shares in the company, valued at approximately $816,644.40. This trade represents a 13.94% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 194,522 shares of company stock worth $9,385,210 over the last 90 days. 0.34% of the stock is owned by insiders.

Boston Scientific Company Profile

(Free Report)

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.

Read More